Tivozanib: Adverse Event Profile and How Toxicities are Managed

Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.

EP: 1.Treatment Options for Patients with Renal Cell Carcinoma (RCC)

EP: 2.Clinical Implications of the TIVO-3 Trial

Now Viewing

EP: 3.Tivozanib: Adverse Event Profile and How Toxicities are Managed

EP: 4.Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

EP: 5.Future Perspectives in Renal Cell Carcinoma (RCC)

Related Videos

Related Content

Advertisement

July 12th 2021

KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

Jamie Cesanek

The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.

Related Content

Advertisement

July 12th 2021

KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

Jamie Cesanek

The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.